Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP17A1 | P05093 | 14/20 | 0.83 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.57 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.52 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.50 |
| ▸ | USP2 | O75604 | 1/20 | 0.50 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | PGR | P06401 | 1/20 | 0.50 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | IDO1 | P14902 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | MAOA | P21397 | 1/20 | 0.50 |
| ▸ | CNR1 | P21554 | 1/20 | 0.50 |
| ▸ | HTR2A | P28223 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9784354 | 0.92 | CYP17A1 (0.76) | CYP17A1CYP19A1CYP11B1CYP11B2MEN1 | |
| SCHEMBL9910964 | 0.91 | CYP17A1 (0.84) | CYP17A1CYP19A1CYP11B1CYP11B2MEN1 | |
| Hydrochloric Acid SCHEMBL9996065 | 0.90 | CYP17A1 (0.78) | CYP17A1CYP19A1CYP3A4 | |
| SCHEMBL9791445 | 0.89 | CYP17A1 (0.71) | CYP17A1CYP3A4 | |
| SCHEMBL5297627 | 0.87 | CYP17A1 (0.82) | CYP17A1CYP19A1CYP11B1CYP11B2CYP3A4 | |
| SCHEMBL7197664 | 0.86 | CYP17A1 (0.64) | CYP17A1CYP19A1CYP11B1CYP11B2MEN1 | |
| SCHEMBL9020912 | 0.86 | CYP17A1 (0.64) | CYP17A1CYP19A1CYP11B1CYP11B2MEN1 | |
| SCHEMBL9784364 | 0.85 | CYP17A1 (0.70) | CYP17A1CYP19A1CYP11B1CYP11B2CYP24A1 | |
| SCHEMBL10520031 | 0.84 | CYP17A1 (0.66) | CYP17A1CYP19A1CYP3A4 | |
| SCHEMBL9784415 | 0.84 | CYP17A1 (0.70) | CYP17A1CYP19A1CYP24A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10414771-B2 | Compounds useful for inhibiting metastasis from cancer and methods using same | DREXEL UNIVERSITY (US) | 2019-09-17 | — | — | US | disclosed |
| US-20180099972-A1 | Compounds Useful for Inhibiting Metastasis from Cancer and Methods Using Same | UNIV DREXEL (US) | 2018-04-12 | — | — | US | disclosed |
| US-20180099972-A1 | Compounds Useful for Inhibiting Metastasis from Cancer and Methods Using Same | UNIV DREXEL (US) | 2018-04-12 | — | — | US | disclosed |
| US-9856260-B2 | Compounds useful for inhibiting metastasis from cancer and methods using same | DREXEL UNIVERSITY (US) | 2018-01-02 | — | — | US | disclosed |
| US-20160264587-A1 | Compounds Useful for Inhibiting Metastasis from Cancer and Methods Using Same | UNIV DREXEL (US) | 2016-09-15 | — | — | US | disclosed |
| US-20160264587-A1 | Compounds Useful for Inhibiting Metastasis from Cancer and Methods Using Same | UNIV DREXEL (US) | 2016-09-15 | — | — | US | disclosed |
| US-9403190-B2 | Liquid composite compositions using non-volatile liquids and nanoparticles and uses thereof | ESIONIC CORP. (US) | 2016-08-02 | — | — | US | disclosed |
| US-9375474-B2 | Compounds useful for inhibiting metastasis from cancer and methods using same | DREXEL UNIVERSITY (US) | 2016-06-28 | — | — | US | disclosed |
| US-9375474-B2 | Compounds useful for inhibiting metastasis from cancer and methods using same | DREXEL UNIVERSITY (US) | 2016-06-28 | — | — | US | disclosed |
| US-9120121-B2 | Liquid composite compositions using non-volatile liquids and nanoparticles and uses thereof | ESIONIC CORP. (US) | 2015-09-01 | — | — | US | disclosed |
| US-8540899-B2 | a mixture of organic solvents, dispersed silica nanostructure particles and an electrolyte; gels used in electronics, capacitors, batteries, fuel cell membranes, dielectrics, electrochromic devices, dye sensitive solar cells, antistatic coatings or gas separation membranes | ESIONIC ES, INC. (US) | 2013-09-24 | — | — | US | disclosed |
| US-20130156761-A1 | Compounds Useful for Inhibiting Metastasis from Cancer and Methods Using Same | Alliance Discovery, Inc. (US) | 2013-06-20 | — | — | US | disclosed |
| US-20130156761-A1 | Compounds Useful for Inhibiting Metastasis from Cancer and Methods Using Same | Alliance Discovery, Inc. (US) | 2013-06-20 | — | — | US | disclosed |
| US-8435993-B2 | Methods of inhibiting metastasis from cancer | PHILADELPHIA HEALTH AND EDUCATION CORPORATION (US) | 2013-05-07 | — | — | US | disclosed |
| US-8435993-B2 | Methods of inhibiting metastasis from cancer | PHILADELPHIA HEALTH AND EDUCATION CORPORATION (US) | 2013-05-07 | — | — | US | disclosed |
| US-20120141471-A1 | Methods of Inhibiting Metastasis from Cancer | Alliance Discovery, Inc. | 2012-06-07 | — | — | US | disclosed |
| US-20120141471-A1 | Methods of Inhibiting Metastasis from Cancer | Alliance Discovery, Inc. | 2012-06-07 | — | — | US | disclosed |
| US-20080209876-A1 | Liquid Composite Compositions Using Non-Volatile Liquids and Nanoparticles and Uses Thereof | ZETTACORE, INC. (US) | 2008-09-04 | — | — | US | disclosed |
| WO-2008098137-A2 | LIQUID COMPOSITE COMPOSITIONS USING NON-VOLATILE LIQUIDS AND NANOPARTICLES AND USES THEREOF | ZETTACORE, INC. (US) | 2008-08-14 | — | — | WO | disclosed |
| EP-0340153-A1 | N-substituted imidazoles, process for their preparation and their use in medicaments | SCHERING AKTIENGESELLSCHAFT (DE) | 1989-11-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180099972-A1 | Compounds Useful for Inhibiting Metastasis from Cancer and Methods Using Same | CX3CR1, CCL2, CCR5 | CYP17A1 979/4885CYP19A1 1280/4885CYP11B1 527/4885 |
| US-10414771-B2 | Compounds useful for inhibiting metastasis from cancer and methods using same | CX3CR1, CCL2, CCR5 | CYP17A1 979/4885CYP19A1 1280/4885CYP11B1 527/4885 |
| US-20120141471-A1 | Methods of Inhibiting Metastasis from Cancer | CX3CR1, CXCR3, CCR5 | CYP17A1 1143/4885CYP19A1 1563/4885CYP11B1 737/4885 |
| US-20130156761-A1 | Compounds Useful for Inhibiting Metastasis from Cancer and Methods Using Same | CX3CR1, CCL2, CCR5 | CYP17A1 979/4885CYP19A1 1280/4885CYP11B1 527/4885 |
| US-20160264587-A1 | Compounds Useful for Inhibiting Metastasis from Cancer and Methods Using Same | CX3CR1, CCL2, CCR5 | CYP17A1 979/4885CYP19A1 1280/4885CYP11B1 527/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.